Endocyte Inc (NASD: ECYT) lost over 60% of its market capitalization after announcement that its cancer drug candidate was shown not to increase survival in a subset of ovarian cancer patients during a phase 2 clinical trial.
ECYT stock dropped below $4 following this news on December 14th and slowly declined all week long.
Done deal? Don’t be so hurry: Endocyte has $138M in cash, very low debt & more drug candidates in the pipeline.
Judging by these numbers we’re positive that company stock is highly undervalued at the current levels. Don’t buying it from us? Well, look at recent Endocyte’s insider filings:
Insiders bought on the open market (December 16th):
Reason? Clear enough: insiders would not buy stock of their company if they are not expecting to make money. They decided to purchase ECYT shares (almost at the same time) and that was a strong signal for us to join ECYT play for the upcoming uptrend.
Trade smart – trade with us!
Endocyte Inc (NASD: ECYT)
3000 Kent Avenue
Endocyte Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Company uses its proprietary technology to create novel small molecule drug conjugates or SMDCs, and companion imaging diagnostics. SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone.